Activation of Plasma Procarboxypeptidase U in Different Mammalian Species Points to a Conserved Pathway of Inhibition of Fibrinolysis

Summary

Carboxypeptidase U (CPU, EC 3.4.17.20) is a recently described basic carboxypeptidase which circulates in plasma as the zymogen procarboxypeptidase U (proCPU). In the current study, we report on the presence of the proCPU/CPU system in different mammalian species – pig, guinea pig, dog, mouse, rabbit, rat and human. The proCPU concentration, determined as carboxypeptidase activity following thrombin-thrombomodulin activation, ranged from 255 U/l (mouse) to 5051 U/l (pig). When the CPU activity is generated during controlled in vitro coagulation by recalcifying citrated plasma, consistently lower activities were found compared to thrombin-thrombomodulin activation. These data indicate that in all species studied the mechanism for activation of proCPU is present. We demonstrate that in all species studied the addition of PTCI – a CPU inhibitor – results in a marked reduction of the lysis time. Albeit the presence of proCPU, the mechanism of activation during coagulation and the substantial reduction of the clot lysis time in the presence of PTCI point to a conserved inhibitory pathway of fibrinolysis.

Keywords

Fibrinolysis - carboxypeptidase U - coagulation - animal species

• References

• 1 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-70.
• 2 Francis CW, Marder VJ. Concepts of clot lysis. Ann Rev Med 1986; 37: 187-204.
• 3 Saito H. α₂-plasmin inhibitor and its deficiency states. J Lab Clin Med 1988; 112: 671-8.
• 4 Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-505.
• 5 Kisiel W. Human plasma protein C. J Clin Invest 1979; 64: 761-9.
• 6 Hendriks D, Scharpé S, van Sande M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-85.
• 7 Hendriks D, Wang W, Scharpé S, Lommaert M, van Sande M. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta 1990; 1034: 86-92.
• 8 Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 933-9.
• 9 Hendriks D, Scharpé S, van Sande M. Partial purification and characterisation of a new arginine carboxypeptidase from human serum. J Clin Chem Clin Biochem 1988; 26: 305.
• 10 Hendriks D, Scharpé S, van Sande M, Lommaert MP. A labile enzyme in fresh human serum interferes with the assay of carboxypeptidase N. Clin Chem 1989; 35: 177.
• 11 Eaton D, Malloy B, Tsai S, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
• 12 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
• 13 Bajzar L, Manuel R, Nesheim M. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
• 14 Bajzar L, Nesheim M, Tracy P. The profibrinolytic effect of protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-100.
• 15 Redlitz A, Nicolini F, Malycky J, Topol E, Plow E. Inducible carboxypeptidase activity: a role in clot lysis in vivo. Circulation 1996; 93: 1328-30.
• 16 Minnema M, Friederich P, Levi M, von dem Borne P, Mosnier L, Meijers J. et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI: in vivo evidence for a role of factor XI as an antifibrinolytic factor. J Clin Invest 1998; 101: 10-4.
• 17 Broze G, Higuchi D. Coagulation-dependent inhibition of fibrinolysis: Role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88: 3815-23.
• 18 Wang W, Hendriks D, Scharpé S. Carboxypeptidase U: a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
• 19 Redlitz A, Tan A, Eaton D, Plow E. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
• 20 Wang W, Boffa M, Bajzar L, Walker J, Nesheim M. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 42: 27176-81.
• 21 Sakharov D, Plow E, Rijken D. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
• 22 Pannell R, Black J, Gurewich V. Complementary modes of action of tissue-type plasminogen activator and prourokinase by which their synergistic effect on clot lysis may be explained. J Clin Invest 1988; 81: 853-9.
• 23 Schatteman K, Goossens F, Scharpé S, Neels H, Hendriks D. Assay of procarboxypeptidase U – a novel determinant of the fibrinolytic cascade – in human plasma. Clin Chem 1999; 45: 807-13.
• 24 Hendriks D, Scharpé S, van Sande M. Assay of carboxypeptidase N activity in serum by liquid-chromatographic determination of hippuric acid. Clin Chem 1985; 31: 1936-9.